Compound class:
Synthetic organic
Comment: The discovery of the TL-77, is described in [2] (and also as compound 9a in [1]). This compound is reported to have improved oral bioavailability compared to rigosertib, and represents a lead anti-mitotic, anti-cancer agent with potential for further development.
|
|
No information available. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Treatment of cells with TL-77 causes a dose-dependent reduction of phosphorylated Cdc25c, which is known substrate of both polo-like kinase 1(PLK1) and CHK1/2. This indicates that TL-77 may act as an inhibitor of PLK1 and/or CHK1/2 (Abstract 3406: Evaluation of (E)-Styrylsulfonyl methylpyridine: A novel kinase inhibitor targeting mitotic pathways, AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC). |